Current knowledge and future directions on cardiovascular disease in diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue SUPPL. 1, 2012, Pages

  Maahs, David M ^a,b   Snell Bergeon, Janet K ^a,b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b Food Science and Human Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLYCOSYLATED PROTEIN; INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD FLOW; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD CARE; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; ECONOMIC DEVELOPMENT; GLYCEMIC CONTROL; GLYCOCALYX; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PREVALENCE; RISK FACTORS;

EID: 84861860843     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0106     Document Type: Note

References (11)

1. Garg SK, DiDomenico D, Switzer S: Ways to reduce cardiovascular disease in diabetes. Diabetes Technol Ther 2012;14(Suppl 1):S-1-S-2.
2. Garg SK: Rising epidemic of diabetes and hypertension in Asia. Diabetes Technol Ther 2012;14:1-2.
3. Lemkes BA, Nieuwdorp M, Hoekstra JBL, Holleman F: The glycocalyx and cardiovascular disease in diabetes: Should we judge the endothelium by its cover? Diabetes Technol Ther 2012;14(Suppl 1):S-3-S-10.
4. Hirsch IB, O'Brien KD: How to best manage glycemia and non-glycemia during the time of acute myocardial infarction. Diabetes Technol Ther 2012;14(Suppl 1):S-22-S-32.
5. Truong UT, Maahs DM, Daniels SR: Cardiovascular disease in children and adolescents with diabetes: Where are we, and where are we going? Diabetes Technol Ther 2012;14(Suppl 1):S-11-S-21.
6. Maahs DM: Cardiovascular disease (CVD) limbo: How soon and low should we go to prevent CVD in diabetes? Diabetes Technol Ther 2012;14:449-452.
7. Home P: Cardiovascular disease and oral agent glucoselowering therapies in the management of type 2 diabetes. Diabetes Technol Ther 2012;14(Suppl 1):S-33-S-42.
8. Lebovitz HE, Banerji MA: Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-43-S-50.
9. Snell-Bergeon JK, Wadwa RP: Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-51-S-58.
10. Pradeepa R, Prabhakaran D, Mohan V: Emerging economies and diabetes and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-59-S-67.
11. Aschner PJ, Ruiz AJ: Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012;14(Suppl 1):S-68-S-74.